Drug profile

The FDA adverse-event record for Thyrotabs

29 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Thyrotabs. Species, reactions, and outcomes follow.

#1488 of 2,679
by report volume (all drugs)
29
adverse-event reports
10.3%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Thyrotabs ranks #1463 of 2679 by total reports (29). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1463
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Thyrotabs has 29 reports now versus 28 in that prior snapshot: 1 more (3.6%).

Report change
+1
Death-coded reports
+0
Death-coded share
−0.4 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Thyrotabs changes

Signature read: death-coded report count at 3 is the most distinctive stamp on Thyrotabs's FDA AER row.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
29
Total Reports
3
Deaths Reported
10.3%
Death-coded share of reports

Active Ingredients

Thyrotabs

Administration Routes

OralUnknown

Species Affected

Dog 29

Most Affected Breeds

Retriever - Labrador 5
Retriever - Golden 4
Greyhound 3
Terrier - Bull - American Pit 2
Spaniel - King Charles Cavalier 1
Great Pyrenees 1
Pinscher - Miniature 1
Spaniel - Springer (unspecified) 1
Chow Chow 1
Shepherd Dog - Australian 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in Neurological) 5
Diarrhoea 4
Not eating 4
Behavioural disorder NOS 4
Vomiting 3
Vestibular disorder NOS 3
Limb weakness 3
Lack of efficacy - NOS 2
Elevated alanine aminotransferase (ALT) 2
Bacterial skin infection NOS 2
Anorexia 2
Urinary incontinence 2

Outcome Breakdown

Ongoing
16 (55.2%)
Recovered/Normal
8 (27.6%)
Outcome Unknown
2 (6.9%)
Euthanized
2 (6.9%)
Died
1 (3.4%)

Thyrotabs Adverse Event Insights

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Thyrotabs (#1488 of 2,679 by report volume); death-coded 10.3%. PlainBreed drug row · death-coded report count stamp 3 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →